How dangerous are non-steroidal anti-inflammatory drugs?
At the extremes of opinion there is an artificial debate between some gastroenterologists who regard non-steroidal anti-inflammatory drugs as an important cause of morbidity and death and some rheumatologists who regard them as free of hazard. These views reflect different facets of risk. Many elderly patients presenting to gastroenterologists with bleeding or perforation are taking non-steroidal anti-inflammatory drugs, which roughly treble the risks.' 2In absolute terms, however, the risk i'emains low (around one in 500 patient years'). None the less, because prescription is so widespread this translates into substantial iatrogenic disease, which would fall with curtailed prescribing.
Do non-steroidal anti-inflammatory drugs retard healing?
Few controlled data address this important question. Trials tend to be small, to amalgamate data on gastric and duodenal ulcers, and to lack appropriate comparisons. Including small ulcers or (inadvertently) erosions in trials may generate better results than occur in clinical practice. One group has consecutively reported evidence that ulcers associated with aspirin are easy and hard to heal.4 In patients continuing to take non-steroidal anti-inflammatory drugs another study showed that the ulcer healed in six weeks in six out of 13 reporting to the regulatory authorities of adverse gastrointestinal drug reactions.9 There may be real differences among the different drugs,'" but rates of reporting are so prone to confounding that we cannot be sure. Ibuprofen seems fairly safe for patients who do not need major analgesia.
Can non-steroidal anti-inflammatory drugs be taken again after ulcers have healed?
Ulcers associated with non-steroidal anti-inflammatory drugs are often silent"' so dyspepsia will not necessarily signal a relapse. This observation raises interesting questions. Do non-steroidal anti-inflammatory drugs reduce ulcer pain or do they provoke complications in pre-existing ulcers, having been given to patients with silent but not painful ulcers?
Ulcers relapse after healing. How far non-steroidal anti-inflammatory drugs enhance the risk has not been quantified. Most prescribers would use maintenance treatment, but the supporting evidence is indirect and there is none to guide choosing a dose. In a study of maintenance treatment given to unselected patients with an ulcer for one to nine years gastrointestinal bleeding was uncommon ( 1 I % of compliant patients); some patients were taking non-steroidal anti-inflammatory drugs, but the number was too small to address management in this group specifically.
Should patients who start taking non-steroidal anti-inflammatory drugs receive prophylaxis?
Whether patients who start taking non-steroidal anti-inflammatory drugs should have prophylaxis is unknown. Several supplementary questions need to be answered.
What is the prophylaxis against? -Failing to suppress erosions"' probably does not matter. But are we correct to assume that ulcer development is the target? As well as being ulcerogenic non-steroidal anti-inflammatory drugs interfere with platelet aggregation and prolong the bleeding time'"; haematemesis often occurs in the short term.' There may be a case for evaluating haemostatic agents for prophylaxis. Whether to start treatment Controversy, however, surrounds continuing or starting treatment with non-steroidal anti-inflammatory drugs in patients with current or past peptic ulcer disease. There are four principal concerns.
Firstly, should non-steroidal anti-inflammatory drugs be given at all? Even after considering the above, some patients with chronic locomotor symptoms find non-steroidal anti-inflammatory drugs undeniably beneficial, and their quality of life is considerably diminished when they are withdrawn. Although the Committee on Safety of Medicines states that nonsteroidal anti-inflammatory drugs should not be given to patients with active peptic ulceration,2 such official advice, predominantly reflecting expectation bias,23 would result in withdrawal of such drugs in up to 30% of patients with chronic rheumatic disease.6 The few studies available, however, show that continuing treatment with the drugs little influences the rates of healing obtained with conventional anti-ulcer treatment'6 24.27: indeed, ulcers may heal spontaneously despite continuing non-steroidal anti-inflammatory drugs.28 If appropriate non-steroidal anti-inflammatory drugs should therefore still be considered.
Secondly, which non-steroidal anti-inflammatory drug should be prescribed? Salicylate and indomethacin should probably be avoided in peptic ulceration because of their additional direct mucosal toxicity246 (in the United Kingdom salicylate is rarely prescribed for arthritis anyway, and indomethacin should be
